CRISPR Therapeutics President Sam Kulkarni On Business Development

CRISPR Therapeutics hopes its partnered lead program in sickle cell disease and beta-thalassemia therapies will generate a product launch within the next four to five years.

DNA
CRISPR Therapeutics sees a product launched in sickle cell disease and beta-thalassemia by 2022 • Source: Shutterstock

One of the pioneers harnessing the CRISPR/Cas-9 to develop human therapeutics, Switzerland-based CRISPR Therapeutics AG is confident its lead program in sickle cell disease and beta-thalassemia therapies will generate a product launch by 2022, and that the ongoing global patent wrangling over the technology won't get in the way of that objective.

CRISPR Therapeutics uses its proprietary CRISPR/Cas9 gene-editing platform to develop gene-based medicines for curing serious diseases at the molecular level...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.